公开(公告)号：US20210171517A1

公开(公告)日：2021-06-10

申请号：US17098675

申请日：2020-11-16

申请人： Shenzhen TargetRx, Inc.

发明人： Yihan Wang ,  Jiuyang Zhao ,  Yixin Ai

IPC分类号： C07D417/14 ,  C07D401/14 ,  A61P35/00

摘要： Provided are a (hetero)arylamide compound as shown in formula (I) having an inhibitory effect on protein kinase activity, a pharmaceutically acceptable salt, a stereoisomer, a solvate or hydrate thereof, a pharmaceutical composition including the compound or a derivative thereof, and a method for preparing the compound. The compound can be used as an irreversible inhibitor for protein kinase, for preparing a plurality of drugs including an anti-tumour drug.

公开(公告)号：US10995103B2

公开(公告)日：2021-05-04

申请号：US16320436

申请日：2017-07-24

申请人： Shenzhen TargetRx, Inc.

发明人： Yihan Wang ,  Jiuyang Zhao

IPC分类号： A61K31/69 ,  A61K9/00 ,  C07B59/00 ,  C07F5/02 ,  A61P13/12 ,  A61P29/00 ,  A61P35/00 ,  A61P35/02 ,  A61P37/00 ,  A61P9/00 ,  C07K5/06 ,  C07H23/00

摘要： A substituted boric acid compound, a pharmaceutical composition including the same, and an application thereof. The substituted boric acid compound is a compound represented by formula (I), or a crystal form, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, a hydrate, or a solvent compound thereof. The boric acid compound has proteasome inhibitory activity, good pharmacodynamic/pharmacokinetic performance, good applicability, and high safety, and can be used for preparing drugs for treating diseases related to proteasomes.

公开(公告)号：US20190263835A1

公开(公告)日：2019-08-29

申请号：US16320436

申请日：2017-07-24

申请人： Shenzhen TargetRx, Inc.

发明人： Yihan Wang ,  Jiuyang Zhao

IPC分类号： C07F5/02 ,  C07B59/00 ,  A61P35/02

摘要： A substituted boric acid compound, a pharmaceutical composition including the same, and an application thereof. The substituted boric acid compound is a compound represented by formula (I), or a crystal form, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, a hydrate, or a solvent compound thereof. The boric acid compound has proteasome inhibitory activity, good pharmacodynamic/pharmacokinetic performance, good applicability, and high safety, and can be used for preparing drugs for treating diseases related to proteasomes.